CATX Stock Forecast & Price Target

Perspective Therapeutics is viewed favorably because its proprietary 212Pb alpha-emitting platform targets multiple high-value oncology settings, including neuroendocrine tumors, metastatic melanoma, and advanced solid tumors, while also creating scarcity value that could attract larger pharma partners seeking an in-house radiopharmaceutical capability. The investment case is further supported by upcoming clinical and operational catalysts, with bamzireotide navoxetan’s pivotal site activation around YE26, VMT01 data expected in late ’26, and a manufacturing network that is expanding to four regional sites by YE27 to strengthen long-term supply reliability. Fundamentally, the company also appears insulated from recent NRC patient-release concerns because DG-8070 explicitly excludes alpha emitters such as Pb-212, while Lutathera’s $225M in 2Q26 revenue and ~$900M FY26E sales provide positive commercial readthrough for the category.

Perspective Therapeutics is exposed to significant fundamental risk because its valuation depends heavily on clinical execution, and poorer-than-expected data for its product candidates could materially impair market potential and investor confidence. Competitive pressure is another major concern, as greater-than-expected rivalry could compress the commercial opportunity across the pipeline, while political, regulatory, and reimbursement uncertainty may limit adoption of marketed products. Although 2Q26 cash and cash equivalents of $237M provide runway into late 2027, the company still posted a diluted EPS loss of ($0.22), underscoring continued operating losses and the need for sustained capital discipline.